HIND News
Vyome Holdings Reports Second Quarter 2026 Results Highlighted by Advancement of Lead VT-1953 Program, Pipeline Expansion and Strong Balance Sheet
Vyome Holdings, Inc. (Nasdaq: HIND, Vyome), a clinical-stage biopharmaceutical company focused on immuno-inflammatory and rare disease conditions, today reports financial results for the second quarter ended June 30, 2026, and provides a corporate update. Krishna Gupta, Chairman, Vyome Holdings...
Business Wire
Vyome Granted Chinese Patent Strengthening Immuno-Inflammation Portfolio
Vyome Holdings, Inc. (NASDAQ: HIND) (Vyome or the Company), a clinical-stage biopharmaceutical company focused on developing differentiated therapies for immuno-inflammatory and rare disease conditions, announces that the China National Intellectual Property Administration (CNIPA) has granted a...
Business Wire
Vyome Holdings Reports First Quarter 2026 Results With Key FDA Filings and Strong Balance Sheet
Vyome Holdings, Inc. (Nasdaq: HIND)(Vyome), a clinical-stage biopharmaceutical company focused on immuno-inflammatory and rare disease conditions, today reports financial results for the first quarter ended March 31, 2026, and provides a corporate update. Krishna Gupta, Chairman of Vyome, said...
Business Wire
Vyome Strikes Deal With Impetis Biosciences, Opening A ~$57B Market Opportunity
Vyome Holdings, Inc. (Vyome) (Nasdaq: HIND) today announced the signing of an agreement with Impetis Biosciences Limited (Impetis), a TATA Enterprise, that gives it exclusive license to develop and commercialize a selective JAK 1/3 inhibitor and a selective JAK1 inhibitor. Janus kinase (JAK...
Business Wire
Vyome Presents Transformational VT-1953 Phase 2 Clinical Study Data at Prestigious AACR 2026
Vyome Holdings, Inc. (Vyome) (Nasdaq: HIND) presented its full Phase 2 investigator initiated study results and preclinical data supporting the efficacy and safety of VT-1953 as a potential treatment for symptoms of Malignant Fungating Wounds (MFW) at the 2026 American Association for Cancer...
Business Wire
Vyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026
Vyome Holdings, Inc. (Vyome) (Nasdaq: HIND) today announced that the company will present its full Phase 2 investigator initiated study results and preclinical data supporting the efficacy and safety...
Business Wire
Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase
Vyome Holdings, Inc., (Vyome) (Nasdaq: HIND), a next-generation inflammation-focused company leveraging the US-India innovation corridor, today announced its financial results and corporate and clinical milestones following its successful listing on Nasdaq. This quarter marks Vyomes first annual...
Business Wire
Livechain Completes Acquisition of Senior, Secured Debt of Humanyze, An MIT Incubated, AI Enabled HR Analytics Company
Livechain, Inc. (Livechain) (OTCX: LICH), a subsidiary of Vyome Holdings, Inc. (Vyome) (Nasdaq: HIND), announced today that it has executed a debt purchase agreement with Remus Capital, a leading...
Business Wire
Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity
Vyome Holdings, Inc. (Vyome) (Nasdaq: HIND) announced the publication of its preclinical data validating the efficacy and safety of VT-1908 as a potential treatment for uveitis in the peer-reviewed...
Business Wire
Vyome Files for VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over the Next 6 Months
Vyome Holdings, Inc. (Vyome) (NASDAQ: HIND), a clinical-stage biopharmaceutical company focused on developing therapies for serious immuno-inflammatory and rare conditions, today announced that it...
Business Wire